A Louisiana court on April 7 asked the FDA to complete its internal review of mifepristone’s safety and gave the agency six months to provide the court with an update on the investigation.

Original title: “FDA probes abortion pill anew after court keeps mail access alive”

The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg base and EQ 25 mg base, held by GlaxoSmithKline, LLC, 2020 Walnut Street, Philadelphia, PA 19104 (GSK). GSK notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Original title: “GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (Leucovorin Calcium) Tablets, EQ 5 mg Base and EQ 25 mg Base”

While federal and state legislators contemplate the next wave of PBM and drug pricing reform, legislatures in Virginia and Ohio have already sent significant legislation addressing prescription drug pricing and pharmacy benefit manager oversight to their respective governors in early 2026. Virginia adopts maximum fair prices and new PBM rules; Ohio creates a standalone PBM licensure and oversight regime with expanded transparency and enforcement The bill would establish a Prescription Drug Affordability Advisory Panel (Panel) and adopt the “maximum fair prices” established under the Inflation Reduction Act for drugs purchased by Virginia-regulated health plans and state employee plans. S.B. 669, which was signed by Governor Spanberger on March 31 and is effective July 1, 2026, expands Virginia’s regulation of carriers and PBMs by adding new prohibited practices — including charging electronic claim processing fees, reversing claims without prior written notice or just cause, reducing payments to effective reimbursement rates not agreed to in a provider agreement, and retroactively denying or reducing claims except in limited circumstances — and by codifying specific acts that constitute prohibited retaliation against pharmacies. A PBM must disclose in writing to the plan sponsor any activity, policy, practice, contract, or arrangement of the PBM that directly or indirectly presents any conflict of interest concerning the PBM’s relationship with or obligation to the plan sponsor.

Original title: “States Continue to Advance New PBM and Drug Pricing Legislation in 2026”

HRSA provides grants through two programs seeking a 1-year funded extension: The Small Health Care Provider Quality Improvement Program (Quality) provides support to rural primary care providers for the planning and implementation of quality improvement activities that improve the quality and delivery of rural health care services. This funded extension extends Quality's 21 award recipients from cohort fiscal year 2022, HRSA-22-093, for a one-time 1-year period (August 1, 2026, to July 31, 2027)

Original title: “Notice of Funded Extension for the Small Health Care Provider Quality Improvement and Delta States Network Development Programs”

The Administration for Children and Families (ACF) within the U.S. Department of Health and Human Services seeks an extension to the existing data collection for the Annual Survey of Refugees (ASR) (Office of Management and Budget #: 0970-0033; Expiration Date: October 30, 2026) through 2027. The ASR is a yearly sample survey of refugee households entering the U.S. in the previous 5 fiscal years (FYs). There are no changes currently requested to the form, but ACF intends to submit a revision req

Original title: “Proposed Information Collection Activity; Office of Refugee Resettlement Annual Survey of Refugees”

This notice acknowledges the receipt of an application from DNV Healthcare USA Inc. (DNV) for continued recognition as a national accrediting organization for its hospital accreditation program to participate in the Medicare or Medicaid programs.

Original title: “Medicare and Medicaid Programs: Application From DNV Healthcare USA Inc. for Continued CMS-Approval of Its Hospital Accreditation Program”

The Office of Refugee Resettlement (ORR) is requesting a 3- year extension with revisions of the Unaccompanied Refugee Minors (URM) Program Application and Withdrawal of URM Program Application or Declination of URM Program Placement Forms (Office of Management and Budget #0970-0550, expiration July 31, 2026). Revisions were made to reduce burden and streamline information collection.

Original title: “Proposed Information Collection Activity; Office of Refugee Resettlement Unaccompanied Refugee Minors Program Application and Withdrawal of Unaccompanied Refugee Minors Program Application or Declination of Unaccompanied Refugee Minors Program Placement Forms”

The Office of Community Services (OCS), Division of Energy Assistance, is requesting to reinstate the Annual Report on Households Assisted by the Low Income Home Energy Assistance Program (LIHEAP) (LIHEAP Household Report; Office of Management and Budget (OMB) #: 0970-0060). The current OMB expiration date is March 31, 2026. Submission of the completed report is one requirement for LIHEAP grant recipients applying for federal LIHEAP block grant funds; the next report is due September 2026. OCS p

Original title: “Proposed Information Collection Activity; Annual Report on Households Assisted by the Low Income Home Energy Assistance Program (LIHEAP)”

The Administration for Children and Families (ACF) is proposing to resume collecting data for the Procedures for Requests from Tribal Lead Agencies to use Child Care and Development Fund (CCDF) Funds for Construction or Major Renovation of Child Care Facilities. This information collection was previously approved by the Office of Management and Budget. The Office of Child Care (OCC) is proposing to extend approval of the information collection with changes, significantly reducing the burden for

Original title: “Submission for Office of Management and Budget Review; Procedures for Requests From Tribal Lead Agencies To Use Child Care and Development Fund Funds for Construction or Major Renovation of Child Care Facilities”

The Department of Health and Human Services, Administration for Children and Families proposes to amend the Block Grants regulations, the Individual Development Account Reserve Funds Established Pursuant to Grants for Assets for Independence regulations, and the Emergency Community Services Homeless Grant Program regulations to eliminate unnecessary or obsolete regulations. The docket on https:/ /www.regulations.gov will include a plain language summary of the NPRM as required.

Original title: “Reducing Bureaucracy and Burden for Community Services Programs”

The Office of Planning, Research, and Evaluation (OPRE) and the Family and Youth Services Bureau in the Administration for Children and Families (ACF) are proposing to collect data for the new Sexual Risk Avoidance Education (SRAE) National Evaluation: Impact and Implementation Study.

Original title: “Submission for Office of Management and Budget Review; Sexual Risk Avoidance Education (SRAE) National Evaluation: Impact and Implementation Study (New Collection)”

Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes.

Original title: “FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes”

If the Trump administration’s proposal passes, the FDA’s budget will be more than $200 million bigger in 2027, with plans to launch new programs that expedite drug development, boost national security and promote “radical transparency.”

Original title: “FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic”

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that LOARGYS (pegzilarginase-nbln), approved F

Original title: “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln)”

This rulemaking proposes to update the prospective payment rates, the outlier threshold, and the wage index for Medicare inpatient hospital services provided by Inpatient Psychiatric Facilities (IPFs), which include psychiatric hospitals and excluded psychiatric units of an acute care hospital or critical access hospital. This rulemaking also proposes refinement of the IPF PPS outlier policy. These changes would be effective for IPF discharges occurring during the fiscal year beginning October 1

Original title: “Medicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update”

This rule proposes changes and updates to the policies and payment rates used under the Skilled Nursing Facility (SNF) Prospective Payment System (PPS) for fiscal year 2027. This proposed rule also updates the requirements for the SNF Quality Reporting Program and the SNF Value-Based Purchasing Program.

Original title: “Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027”

The Administrator of the World Trade Center (WTC) Health Program has received several petitions (Petitions 029, 034, 035, and 062) to add "hepatic steatosis" or "fatty liver disease" to the List of WTC-Related Health Conditions. Upon reviewing the scientific and medical literature, including information provided by the petitioners, the Administrator has determined that there is insufficient evidence available to support taking further action at this time regarding hepatic steatosis. The Administ

Original title: “World Trade Center Health Program; Petitions 029, 034, 035, and 062-Hepatic Steatosis; Finding of Insufficient Evidence”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled National Notifiable Diseases Surveillance System (NNDSS). This data collection provi

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Public Health/Public Safety Strategies to Reduce Drug Overdose Data Collection. The

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”